On May 23, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for the treatment of unresectable or metastatic solid tumors with the biomarker microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Read more